R1 RCM Inc. found using ticker (RCM) now have 8 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 16 and 10 with the average target price sitting at 14.63. With the stocks previous close at 13.88 this now indicates there is a potential upside of 5.4%. The 50 day MA is 12.41 while the 200 day moving average is 11.34. The company has a market capitalisation of $1,571m. Find out more information at: http://www.r1rcm.com
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers. The company also provides modular services comprising physician advisory services, which assists hospitals in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; and revenue capture services, including charge capture, charge description master maintenance, and pricing services. It serves healthcare providers, including health systems and hospitals, physicians groups, and municipal and private emergency medical service providers, as well as intermountain homecare, hospice and palliative care, and durable medical equipment and infusion therapy business. The company was formerly known as Accretive Health and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was founded in 2003 and is headquartered in Chicago, Illinois.